232 related articles for article (PubMed ID: 23404447)
21. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
22. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
23. VIGAS and beyond: the impact of HCMV-infection and its treatment in glioblastoma.
Ottenhausen M; Bodhinayake I; Schaefer PM; Boockvar JA
Neurosurgery; 2014 Feb; 74(2):N23-4. PubMed ID: 24435151
[No Abstract] [Full Text] [Related]
24. Challenging cytomegalovirus data in glioblastoma.
Wick W; Wick A; Platten M
Neuro Oncol; 2014 Jan; 16(1):165. PubMed ID: 24353326
[No Abstract] [Full Text] [Related]
25. VIGAS and beyond: the impact of HCMV-infection and its treatment in glioblastoma.
Ottenhausen M; Bodhinayake I; Schaefer PM; Boockvar JA
Neurosurgery; 2014 Apr; 74(4):N17-8. PubMed ID: 24642991
[No Abstract] [Full Text] [Related]
26. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
27. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
Montoya JG; Kogelnik AM; Bhangoo M; Lunn MR; Flamand L; Merrihew LE; Watt T; Kubo JT; Paik J; Desai M
J Med Virol; 2013 Dec; 85(12):2101-9. PubMed ID: 23959519
[TBL] [Abstract][Full Text] [Related]
28. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
[TBL] [Abstract][Full Text] [Related]
29. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
30. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
31. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
32. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
Welker H; Farhan M; Humar A; Washington C
Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
[TBL] [Abstract][Full Text] [Related]
33. [Inconclusive data].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Jul 2-15; 111(27-28):1192. PubMed ID: 25162111
[No Abstract] [Full Text] [Related]
34. [Questionable effect of antiviral therapy in malignant brain tumors].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
[No Abstract] [Full Text] [Related]
35. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
36. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
[TBL] [Abstract][Full Text] [Related]
37. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients.
Wéclawiak H; Kamar N; Mengelle C; Guitard J; Esposito L; Lavayssière L; Cointault O; Ribes D; Rostaing L
J Med Virol; 2008 Jul; 80(7):1228-32. PubMed ID: 18461614
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
